These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 39206997)

  • 1. Analysis of efficacy and safety for the combination of tislelizumab and regorafenib in advanced hepatocellular carcinoma: A prospective clinical study.
    Sun P; Zhang Y; Tian S; Cui K; Zhong J; Zhang C; Wang D; Zhang B; Shi X; Li Z
    J Cancer Res Ther; 2024 Aug; 20(4):1344-1349. PubMed ID: 39206997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TACE plus lenvatinib and tislelizumab for intermediate-stage hepatocellular carcinoma beyond up-to-11 criteria: a multicenter cohort study.
    Chen S; Shuangyan T; Shi F; Cai H; Wu Z; Wang L; Ma P; Zhou Y; Mai Q; Wang F; Lai J; Chen X; Chen H; Guo W
    Front Immunol; 2024; 15():1430571. PubMed ID: 39131156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatic arterial infusion chemotherapy, lenvatinib plus programmed cell death protein-1 inhibitors: A promising treatment approach for high-burden hepatocellular carcinoma.
    Fu S; Xu Y; Mao Y; He M; Chen Z; Huang S; Li D; Lv Y; Wu J
    Cancer Med; 2024 May; 13(9):e7105. PubMed ID: 38686567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regorafenib with immunotherapy versus regorafenib alone as second-line treatment for hepatocellular carcinoma: A multicenter real-world study.
    Qiao L; He W; Wang G; Chen H; Huang F; Zhang B; Qiu Y; Liu S; Huang Z; Yuan Y; Qiu J; Yuan Y; Li B
    Cancer Med; 2024 May; 13(9):e7236. PubMed ID: 38716585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world systemic sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Korea.
    Lee MJ; Chang SW; Kim JH; Lee YS; Cho SB; Seo YS; Yim HJ; Hwang SY; Lee HW; Chang Y; Jang JY
    Invest New Drugs; 2021 Feb; 39(1):260-268. PubMed ID: 32749658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of TACE Combined with Regorafenib versus TACE Combined with Camrelizumab in Hepatocellular Carcinoma With Untreatable Progression After TACE Combined with Sorafenib Therapy: A Case Control Study.
    Ren Y; Liu Y; Song S; Zheng C
    Cancer Control; 2024; 31():10732748241275004. PubMed ID: 39163892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative efficacy and safety for second-line treatment with ramucirumab, regorafenib, and cabozantinib in patients with advanced hepatocellular carcinoma progressed on sorafenib treatment: A network meta-analysis.
    Chen J; Wang J; Xie F
    Medicine (Baltimore); 2021 Sep; 100(38):e27013. PubMed ID: 34559096
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study.
    Bruix J; Tak WY; Gasbarrini A; Santoro A; Colombo M; Lim HY; Mazzaferro V; Wiest R; Reig M; Wagner A; Bolondi L
    Eur J Cancer; 2013 Nov; 49(16):3412-9. PubMed ID: 23809766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The second-line treatment of hepatocellular carcinoma with CalliSpheres drug-eluting bead transarterial chemoembolization combined with regorafenib: A safety and efficacy analysis.
    Liu S; Liu C; Wang Q; Liu Y; Wang D; Zhao G; Yu G
    Ir J Med Sci; 2024 Jun; 193(3):1215-1222. PubMed ID: 38300460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of second-line therapies for advanced hepatocellular carcinoma: a network meta-analysis of randomized controlled trials.
    Lu F; Zhao K; Ye M; Xing G; Liu B; Li X; Ran Y; Wu F; Chen W; Hu S
    BMC Cancer; 2024 Aug; 24(1):1023. PubMed ID: 39160484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma.
    Kelley RK; Mollon P; Blanc JF; Daniele B; Yau T; Cheng AL; Valcheva V; Marteau F; Guerra I; Abou-Alfa GK
    Adv Ther; 2020 Jun; 37(6):2678-2695. PubMed ID: 32424805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy and safety of Radiofrequency ablation combined with Lenvatinib plus Sintilimab in Unresectable Hepatocellular Carcinoma: a real-world study.
    Wang X; Sun X; Lei Y; Fang L; Wang Y; Feng K; Xia F
    BMC Cancer; 2024 Aug; 24(1):1036. PubMed ID: 39174912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial.
    Xu J; Shen J; Gu S; Zhang Y; Wu L; Wu J; Shao G; Zhang Y; Xu L; Yin T; Liu J; Ren Z; Xiong J; Mao X; Zhang L; Yang J; Li L; Chen X; Wang Z; Gu K; Chen X; Pan Z; Ma K; Zhou X; Yu Z; Li E; Yin G; Zhang X; Wang S; Wang Q
    Clin Cancer Res; 2021 Feb; 27(4):1003-1011. PubMed ID: 33087333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of tislelizumab plus lenvatinib as first-line treatment in patients with unresectable hepatocellular carcinoma: a multicenter, single-arm, phase 2 trial.
    Xu L; Chen J; Liu C; Song X; Zhang Y; Zhao H; Yan S; Jia W; Wu Z; Guo Y; Yang J; Gong W; Ma Y; Yang X; Gao Z; Zhang N; Zheng X; Li M; Su D; Chen M
    BMC Med; 2024 Apr; 22(1):172. PubMed ID: 38650037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Envafolimab plus lenvatinib and transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: a prospective, single-arm, phase II study.
    Chen Y; Zhang J; Hu W; Li X; Sun K; Shen Y; Zhang M; Wu J; Gao S; Yu J; Que R; Zhang Y; Yang F; Xia W; Zhang A; Tang X; Bai X; Liang T
    Signal Transduct Target Ther; 2024 Oct; 9(1):280. PubMed ID: 39384742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sorafenib-Regorafenib Sequential Therapy in Advanced Hepatocellular Carcinoma: A Single-Institute Experience.
    Ueshima K; Nishida N; Kudo M
    Dig Dis; 2017; 35(6):611-617. PubMed ID: 29040994
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regorafenib: a newly approved drug for advanced hepatocellular carcinoma.
    Kyrochristos ID; Ziogas DE; Roukos DH
    Future Oncol; 2017 Aug; 13(19):1665-1668. PubMed ID: 28613123
    [No Abstract]   [Full Text] [Related]  

  • 18. Benefit-Risk Summary of Regorafenib for the Treatment of Patients with Advanced Hepatocellular Carcinoma That Has Progressed on Sorafenib.
    Pelosof L; Lemery S; Casak S; Jiang X; Rodriguez L; Pierre V; Bi Y; Liu J; Zirkelbach JF; Patel A; Goldberg KB; McKee AE; Keegan P; Pazdur R
    Oncologist; 2018 Apr; 23(4):496-500. PubMed ID: 29386313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TACE combined Lenvatinib plus Camrelizumab versus TACE alone in efficacy and safety for unresectable hepatocellular carcinoma: a propensity score-matching study.
    Tang Z; Bai T; Wei T; Wang X; Chen J; Ye J; Li S; Wei M; Li X; Lin Y; Tang J; Li L; Wu F
    BMC Cancer; 2024 Jun; 24(1):717. PubMed ID: 38862932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multicenter retrospective analysis of the safety and efficacy of regorafenib after progression on sorafenib in Korean patients with hepatocellular carcinoma.
    Yoo C; Park JW; Kim YJ; Kim DY; Yu SJ; Lim TS; Lee SJ; Ryoo BY; Lim HY
    Invest New Drugs; 2019 Jun; 37(3):567-572. PubMed ID: 30523474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.